Abbott reports Q3 2026 earnings, tightens FY EPS guidance and announces Nutrition unit spin‑off
+3 new sources since this summary was written
Abbott Laboratories posted third‑quarter 2026 adjusted earnings of $1.42 per share on revenue of $13.013 billion, a 14.5% year‑over‑year increase. The company reaffirmed its full‑year adjusted EPS guidance at $5.50‑$5.55 and said it will spin off its Nutrition segment by 2027. CEO Robert B. Ford highlighted balanced growth across its portfolio and a strong pipeline of new product approvals.
Why it matters
The unchanged FY EPS guidance signals that earnings expectations remain stable despite the spin‑off, which could reshape the company’s revenue mix and valuation. Investors will need to assess the impact of separating the $8.5 billion‑annual Nutrition business on future earnings and cash flow.
Key facts
- 1Adjusted diluted EPS for Q3 2026 was $1.42. prnewswire.com
- 2GAAP diluted EPS for Q3 2026 was $0.53. prnewswire.com
- 3Q3 2026 revenue was $13.013 billion, up 14.5% YoY. quiverquant.com
- 4Full‑year 2026 adjusted EPS guidance was tightened to $5.50‑$5.55. prnewswire.com
- 5Abbott announced a plan to spin off its Nutrition unit by 2027. investing.com
- 6Nutrition segment generates about $8.5 billion in annual sales. investing.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.